title: [Lennox-Gestaut syndrome: therapeutic aspects].
abstract: The Lennox-Gastaut Syndrome is one of the most refractory form of epilepsy and a variety of compounds, such as traditional antiepileptics, "new anticonvulsants" and non-anticonvulsant drugs has been tested. ACTH and, among the traditional antiepileptics. Clonazepam and Sodium Valproate showed the most favorable effects. The immediate (within 6 months) therapeutic response to ACTH and Clonazepam is satisfactory, with a more than 50% reduction of seizures in about one half of patients; after one year, however, only a small percentage of cases (7-10%), rather close to that with spontaneous remission, shows some therapeutic benefit. Valproate, when used as a single drug, produces a decrease in seizures (greater than 50%) in 25-30% of pts. A list of compounds, such as amphetamine, taurine, amantadine, allopurinol and, among the new putative antiepileptics, cinromide and gamma-vinyl-GABA, has been tested with some occasionally observed improvement in seizure control. None of these compounds, however, is of really proven efficacy. An acquired general rule of treatment is to avoid complex polypharmacy and overdose; there is in fact good evidence that making the child drowsy will greatly increase the number of fits.
authors.affiliation: Istituto di Scienze Neurologiche e Neurochirurgiche, Università, Messina.
authors.forename: F
authors.initials: F
authors.lastname: Pisani
authors.forename: G
authors.initials: G
authors.lastname: Oteri
authors.forename: R
authors.initials: R
authors.lastname: Di Perri
mesh_terms: D000927:Anticonvulsants / Q000627:therapeutic use*; D004827:Epilepsy / Q000188:drug therapy*; D006801:Humans; D013577:Syndrome
chemical_list: D000927:Anticonvulsants
vernacular_title: La sindrome di Lennox-Gastaut: aspetti terapeutici.